WhatsApp AI help versus paper leaflets for people new to hearing aids
Tests WhatsApp AI help for people new to hearing aids.
Key facts
- Who runs it
- University of Pretoria
- Where
- South Africa2 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- WhatsApp AI Support vs Paper Support for First-Time Hearing Aid Users
- Status
- Recruiting
- People taking part
- 66 people, planned
- Started
- 6 Jul 2026
- Expected to end
- 15 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Go Ultra Hearing Aids
- WhatsApp-delivered AI-enabled support
- Paper-Based Support Programme
- Record updated
- 23 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with hearing loss in both ears who are getting hearing aids for the first time. It compares support through WhatsApp, including an AI chat helper, with support from a paper leaflet.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- Mild to severe hearing loss in both ears (20 to < 80 dB PTA), confirmed at the first study tests.
- Earlier treatment
- First-time hearing aid users.
- Biomarker or test result
- Hearing test result (PTA) of 20 to < 80 dB in both ears.
Main reasons for not taking part
- Hearing loss too severe (≥80 dB HL PTA) or normal hearing (<20 dB HL PTA)
- Hearing loss in only one ear
- Middle ear problems, such as ear infection or fluid draining from the ears
- No WhatsApp of your own, or only through another person's WhatsApp
- Not able to use English, isiXhosa or Sepedi well enough, or not able to take part for the 5-week follow-up
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- 18 years and older
- Confirmed mild to severe (20 to < 80 dB PTA in both ears) hearing loss (determined during baseline assessments)
- Willing/available to commit to 5-week follow-up
- Must have access to their own personal WhatsApp
- Functional proficiency in English, isiXhosa, or Sepedi sufficient to provide informed consent and to self-complete the study outcome measures in one of these three languages, as judged by the recruiting CHW during the screening conversation
Who cannot take part
- Younger than 18 years
- Hearing loss too severe (≥80 dB HL PTA)
- Normal hearing (<20 dB HL PTA)
- Middle ear pathology, such as otitis media, active drainage from the ears
- Unwilling/unavailable to commit to a 5-week follow-up
- Unilateral hearing loss
- No access to WhatsApp/only has access via another individual's WhatsApp
- Home language other than English, isiXhosa, or Sepedi, where the individual does not have functional proficiency in any of these three languages
This trial is currently available in South Africa.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to advance hearing care in low- and middle-income countries (LMICs) through the rigorous evaluation and optimization of innovative interventions and technologies. This study encompasses the following key aim:
Read full original descriptionShow less
This study aims to evaluate the effectiveness of a WhatsApp-delivered AI-enabled support and acclimatization programme for adults receiving preset hearing aids in low-resource community settings. The AI-enabled programme combines two complementary components delivered through the same WhatsApp channel: (i) a structured push programme of 16 voice notes and images delivered over four weeks, and (ii) an on-demand artificial-intelligence (AI) conversational support agent available throughout the four-week intervention period. The primary objective is to determine whether this WhatsApp-delivered AI-enabled programme results in superior hearing aid self-efficacy compared to receiving the equivalent core information in a paper-based pamphlet at the time of fitting. By comparing hearing aid self-efficacy, hearing aid outcomes, and user engagement between the intervention (WhatsApp AI-enabled) and control (paper-based) groups, this study seeks to establish whether AI-enabled digital delivery provides superior support and leads to better self-efficacy for first-time hearing aid users compared to traditional paper-based methods.
The 2 groups in the trial
- Experimental group (WhatsApp-delivered AI-enabled support)Treatment being tested
Experimental group (WhatsApp-delivered AI-enabled support): receives the AI-enabled support and acclimatization programme delivered exclusively via WhatsApp, comprising (i) 16 structured voice notes and images delivered over four weeks and (ii) on-demand access to the AI conversational support agent throughout the four-week intervention period.
Treatment: Go Ultra Hearing Aids and WhatsApp-delivered AI-enabled support
- Control group (paper-based support)Existing treatment, for comparison
Control group (paper-based support): receives the equivalent core support information delivered exclusively in a printed pamphlet at the time of fitting.
Treatment: Go Ultra Hearing Aids and Paper-Based Support Programme
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A WhatsApp-Delivered AI-Enabled Support Programme Versus Paper-Based Support for First-Time Hearing Aid Users in Low-Resource Communities: A Randomized Controlled Trial
- Plain-language title
- WhatsApp AI help versus paper leaflets for people new to hearing aidsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 23 July 2026